ArticleRadiation oncology (London, England)2026
Combined re-radiation therapy and regional or capacitive hyperthermia as a part of multimodal treatment for locoregional breast cancer recurrences in previously irradiated areas.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyperthermia (HT) enhances the effects of radiotherapy (RT) and has shown benefit in recurrent breast cancer. Most existing studies focus on conventional superficial HT, whereas the efficacy of regional hyperthermia (RHT) and capacitive hyperthermia (CHT) in previously irradiated areas remains underexplored.
methodsPatients with locoregional breast cancer recurrences previously treated with RT were included in this retrospective analysis. Re-irradiation was delivered in combination with RHT or CHT and was integrated into an individualized multimodal treatment concept. HT was applied once or twice weekly immediate following RT, with temperature monitoring performed for RHT. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and toxicity.
resultsA total of 15 patients with 17 locoregional recurrences were included. Patients received re-RT with a median dose of 50 Gy and a median of 7 HT sessions (range, 1-24 sessions; Interquartile range (IQR), 5.5-10). After a median follow-up of 30.1 months (range, 5-76 months; IQR, 13-43) two patients experienced local progression during follow-up. The estimated 2-year PFS was 75%, and OS was 60% at last follow-up. Acute and late toxicities were limited to grade 1-2 events, with no grade ≥ 3 toxicity observed.
conclusionThis retrospective analysis demonstrates the feasibility of combining RHT or CHT with multimodal treatment in patients with recurrent breast cancer and provides encouraging preliminary clinical outcomes. Despite the limitations, these findings support the integration of RHT and CHT into salvage treatment strategies and justify further prospective investigation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.